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Tissue kallikrein attenuates salt-induced renal fibrosis
by inhibition of oxidative stress
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Tissue kallikrein attenuates salt-induced renal fibrosis by inhi-
bition of oxidative stress.
Background. High salt intake induces hypertension, cardiac
hypertrophy, and progressive renal damage. Progressive re-
nal injury is the consequence of a process of destructive fi-
brosis. Using gene transfer approach, we have shown that the
tissue kallikrein-kinin system (KKS) plays an important role
in protection against renal injury in several hypertensive rat
models. In this study, we further investigated the effect and po-
tential mechanisms mediated by kallikrein on salt-induced renal
fibrosis.
Methods. Adenovirus harboring the human tissue kallikrein
gene was delivered intravenously into Dahl salt-sensitive (DSS)
rats on a high salt diet for 4 weeks. Two weeks after gene deliv-
ery, the effect of kallikrein on renal fibrosis was examined by
biochemical and histologic analysis.
Results. Kallikrein gene delivery resulted in reduced blood
urea nitrogen (BUN), urinary protein and albumin levels in
DSS rats on a high salt diet. Expression of recombinant human
tissue kallikrein was detected in the sera and urine of rats in-
jected with the kallikrein gene. Histologic investigation showed
that kallikrein gene delivery significantly reduced glomerular
and tubular fibrosis scores and collagen deposition, as well as
renal cell proliferation, compared to rats on a high salt diet
injected with control virus. Kallikrein gene transfer signifi-
cantly increased nitric oxide and cyclic guanosine monophos-
phate (cGMP) levels in conjunction with reduced salt-induced
nicotinamide adenine dinucleotide/nicotinamide adenine din-
ucleotide phosphate (NADH/NADPH) oxidase activity, su-
peroxide production, transforming growth factor-b1 (TGF-b1)
mRNA and protein levels, and TGF-b1 immunostaining.
Conclusion. These results indicate that tissue kallikrein pro-
tects against renal fibrosis in hypertensive DSS rats through in-
creased nitric oxide bioavailability and suppression of oxidative
stress and TGF-b expression.
Renal fibrosis is the final common pathway to end-stage
renal failure. Increased matrix protein synthesis and de-
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creased degradation of matrix protein all appear to in-
crease the accumulation of extracellular matrix (ECM),
which leads to glomerulosclerosis and tubulointerstitial
scarring [1–3]. The extent and severity of interstitial and
glomerular lesions are also known to reflect the deterio-
ration of renal function [4–5]. Fibrogenic factors trans-
forming growth factor-b (TGF-b), angiotensin II, and
plasminogen activator inhibitor-1 (PAI-1) are the main
contributors to renal fibrosis [2, 6]. TGF-b , a premier
fibrosis-promoting molecule, exerts biologic effects on
target cells via binding to specific cell membrane recep-
tors and activation of intracellular signaling pathways
that ultimately affect target cell gene transcription, in-
cluding expression of matrix genes, genes of inhibitors of
matrix-degrading enzymes, and matrix-binding receptors
[2, 7, 8]. TGF-b1 synthesis and ECM gene expression are
induced by reactive oxygen species (ROS) in cultured
human mesangial cells [9]. ROS play an important role
in the pathogenesis of acute and chronic renal diseases
as characterized by varying degree of decreased renal
function, increased proliferation of renal cells, and pro-
gressive accumulation of ECM proteins [10–13]. These
findings suggest that oxidative stress may underlie the
development and progression of renal fibrosis.
High salt intake in Dahl salt-sensitive (DSS) rats results
in enhanced production of superoxide radicals within the
arterioles and venules in addition to elevated levels of hy-
drogen peroxide in plasma [14]. A recent study showed
that oxidative stress contributes to salt-sensitive hyper-
tension in DSS rats and the accompanying renal dam-
age [15]. Antioxidant treatment with vitamin E markedly
reduced blood pressure and ameliorated renal injury in
DSS rats on a high salt diet [16]. High salt intake in DSS
rats also increases TGF-b1 transcription as well as latent
TGF-b1 secretion from sclerotic glomeruli and intrarenal
vascular walls [17]. These results indicate that increased
expression of TGF-b1 induced by a high salt diet may be
related to ECM accumulation in both thickened vascular
walls and sclerotic glomeruli of hypertensive individuals.
Tissue kallikrein cleaves low-molecular-weight kinino-
gen substrate to release kinin by limited proteolysis [18,
19]. By binding to endothelial bradykinin B2 receptors,
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kinin stimulates release of nitric oxide, leading to in-
creased local blood flow and smooth muscle relaxation
[20]. In addition, nitric oxide suppresses the superoxide-
generating activity of NADH/NADPH oxidase and the
levels TGF-b1 and PAI-1 in vascular smooth muscle cells
and mesangial cells [21–23]. Taken together, these find-
ings indicate that increased nitric oxide production may
play a protective role in reducing oxidative stress and fi-
brosis. It has been shown that renal and urinary kallikrein
levels are reduced in DSS rats on a high salt diet (8%
NaCl) as compared to DSS rats on a normal diet [24].
We previously demonstrated that a continuous supply of
tissue kallikrein by adenovirus-mediated gene transfer
reduced blood pressure, improved renal function, and re-
duced renal injury in DSS rats on a high salt diet [25]. In
the present study, we further investigated the effect of
kallikrein on renal cell proliferation and fibrosis as well
as the potential factors mediating kallikrein’s action in
the antifibrogenic process.
METHODS
Animals
DSS rats (male, 4 weeks old) (Sprague-Dawley Harlan,
Indianapolis, IN, USA) were used in this study. Rats were
divided into two groups. The first group was fed standard
rat chow (0.4% NaCl) and the other group was fed a
high salt diet (4% NaCl) (Harlan Teklad, Madison, WI,
USA). All rats had free access to water. All procedures
complied with the standards for care and use of animal
subjects as stated in the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Resources,
National Academy of Sciences, Bethesda, MD, USA).
Preparation of replication-deficient adenovirus
vector Ad.CMV-CHK-4F2
Human tissue kallikrein plasmid cDNA (cHK) along
with cytomegalovirus (CMV) promoter was inserted at
XhoI and BglII site of Kan-pShut plasmid. Subsequently,
the 4F2 enhancer and bovine growth hormone poly (A)
sequence were inserted at XhoI site in the Kan-pShut vec-
tor. The Kan-pShut plasmid was modified from pHM4
plasmid (kindly provided by Dr. Mark A. Kay, Stan-
ford University Medical Center, Stanford, CA, USA)
and engineered by insertion of a kanamycin-resistant
gene expression unit. The expression cassettes of hu-
man tissue kallikrein cDNA along with the kanamycin-
resistant gene were released with I-CeuI and PI-SceI and
inserted at the same sites of pAdHM4 plasmid, a back-
bone vector of E1/E3-deleted adenovirus. The expres-
sion cassettes of human tissue kallikrein cDNA along
with the E1/E3-deleted adenoviral backbone DNA were
released with PacI and transfected into human embry-
onic kidney (HEK) 293 cells. The E1/E3-deleted aden-
ovirus, Ad.CMV-cHK-4F2, was generated and amplified
through six passages and purified as previously described
[26].
Intravenous delivery of adenoviral vectors
DSS rats fed a high salt diet containing 4% NaCl for
4 weeks were randomly divided into two groups and
intravenously injected through the tail-vein with either
Ad.CMV-cHK-4F2 (N = 7) or control virus encoding the
luciferase gene Ad.CMV-Luc (N = 6) at a dosage of 1.6 ×
1010 pfu (plaque formation unit) per rat.
Urine and blood collection
Twenty-four–hour urine was collected from rats in
metabolic cages at 7 days post-gene delivery. In order
to eliminate contamination of urine samples, animals re-
ceived only water during the 24-hour collection period.
Urine was collected and centrifuged at 1,000 × g to re-
move particles. The supernatant of urine was used for
further analysis. Rat serum was collected at various time
points after gene delivery.
Assays for blood urea nitrogen (BUN), human tissue
kallikrein, urinary protein, albumin, nitric oxide,
and cyclic guanosine monophosphate (cGMP)
BUN levels were determined using a modified urease-
indophenol method [27]. Human tissue kallikrein levels
in rat urine and sera were determined by an enzyme-
linked immunosorbent assay (ELISA) as previously de-
scribed [28]. Radioimmunoassays of urinary cGMP and
albumin were examined at 7 days post-gene transfer ac-
cording to the published protocols [29, 30]. Total urinary
protein levels were measured by Lowry’s method [31].
Nitric oxide levels in urine samples collected at 7 days af-
ter gene delivery were measured by a fluorometric assay
for nitrite/nitrate [32].
Tissue preparation
Rats were anaesthetized with pentobarbital (50 mg/kg
body weight, intraperitoneally) and perfused with saline
through left ventricle. Kidneys were removed, cleaned,
blotted, and weighed. A slice of kidney section was
preserved in zinc formalin (10% zinc dichromate, 4%
formaldehyde, and 0.9% NaCl) and embedded in paraf-
fin. Sections 4 lm in thickness were prepared for histo-
chemical and immunohistochemical studies.
A part of the kidney was homogenized in guanidine
isothiocyanate solution and stored at −80◦C for total
RNA extraction. A piece of renal cortex was snap-frozen
in liquid nitrogen and stored in the −80◦C for biochemical
assays.
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Western blot analysis
Frozen renal cortex was homogenized by sonicator
(The Vir Tis Company, Inc., Gardiner, NY, USA) in
radioimmunoprecipitation buffer (RIPA) [50 mmol/L
Tris-HCl, 150 mmol/L NaCl, 1 mmol/L disodium
ethylenediaminetetraacetic acid (EDTA), 0.1 mmol/L
egtazic acid (EGTA), 1.0% Nonidet P-40, 0.1% sodium
dodecyl sulfate (SDS), and 0.5% sodium deoxycholate]
with protease inhibitors (Protease Inhibitor Cocktail)
Sigma Chemical Co., St. Louis, MO, USA). Samples were
centrifuged at 15,000 × g for 30 minutes at 4◦C, and the
supernatant was collected. Total protein of each sample
was determined by Bio-Rad DC Protein Assay (Bio-Rad,
Hercules, CA, USA). Samples containing 150 lg of to-
tal protein were boiled in SDS sample loading buffer
for 5 minutes, resolved in 10% SDS-polyacrylamide gel
electrophoresis (PAGE), and then transferred onto a ni-
trocellulose membrane. Following incubation in block-
ing buffer TBST (5% nonfat dry milk in Tris-buffered
saline, pH 7.6, and 0.1% Tween 20), the membrane was
incubated with TGF-b1 antibody overnight at 4◦C (1:200
dilution) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or b-actin (1:3000) (Sigma Chemical Co.). The
membrane was then washed three times by TBST and in-
cubated at room temperature for 1 hour with horseradish
peroxidase-conjugated antirabbit IgG solution (1:10,000
dilution) (New England Biolab, Beverly, MA, USA) in
the blocking solution. Immunoreactive bands were vi-
sualized using the enhanced chemiluminescence (ECL)
detection system (Amersham, Piscataway, NJ, USA) and
chemiluminescence was detected by exposure to Kodak
x-ray films.
RNA extraction and Northern blot analysis
Total RNA from the kidney was isolated by using
guanidine isothiocyanate as previously described [28].
Ten micrograms of total RNA from the kidney was sub-
jected to electrophoresis in a 2.2 mol/L formaldehyde-
1% agarose gel, transferred onto Hybond-N nylon
membranes (Schleicher & Schuell Inc., Keene, NH,
USA), and then fixed by ultraviolet crosslinking. The
membrane was prehybridized for at least 2 hours at
42◦C in hybridization solution [5 × standard saline cit-
rate (SSC), 5 × Denhardt’s solution, 0.1 mg/mL of
salmon sperm DNA, 0.1% SDS, and 50% formamide].
Murine TGF-b1 cDNA fragment, 974 bp, was released
from mTGF-b1-A plasmid DNA (kindly provided by Dr.
Moses, Vanderbilt University Medical Center, Nashville,
TN, USA) by SmaI digestion. DNA fragment was elec-
trophoresed and purified by Qiaex II gel extraction
kit (Qiagen Inc., Valencia, CA, USA). cDNA probes
for TGF-b1 and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) were labeled with 32P-dexoycytidine
triphosphate (dCTP) by random primer method and
the membranes were hybridized at 42◦C overnight
[17]. Autoradiography was performed by the standard
method. The densitometric value of each mRNA was
corrected against that of GAPDH. The ratio of each
mRNA/GAPDH RNA was averaged in each group.
Detection of superoxide by ferricytochrome
c reduction assay
Superoxide production in renal extracts was measured
as the superoxide dismutase (SOD)-inhibitable reduction
of cytochrome c at 550 nm according to modified previous
protocol [33, 34]. Samples were mixed with cytochrome c
(final concentration 1 mg/mL), with or without SOD (fi-
nal concentration 510 U/mL). The absorbance was read
at 550 nm against a distilled-water blank. Reduction of
cytochrome c in the presence of SOD was subtracted
from values without SOD. The difference in absorbance
between comparable wells with or without SOD was con-
verted to equivalent O2− production by using molar ex-
tinction coefficient for cytochrome c (21.0 × 103 cm−1
mol/L−1).
Determination of NADH/NADPH oxidase activity
NADH/NADPH oxidase activity was measured by
lucigenin-enhanced chemiluminescent detection of su-
peroxide in a luminometer (TD-20/20) (Turner Designs,
Sunnyvale, CA, USA) according to the previously pub-
lished protocol [34]. Briefly, reaction buffer contained
50 mmol/L phosphate buffer (pH 7.5), 0.01 mmol/L
EDTA, 250 lmol/L lucigenin as electron acceptor, and
2 mmol/L NADH or NADPH. The reaction was started
by addition of kidney homogenates (100 to 300 lg pro-
tein). Luminescence was measured as the rate of photon
counts per mg protein following subtraction of the counts
obtained from a buffer blank.
Histochemical investigation
Four micrometer thick sections were cut and stained
with sirius red [35] and then analyzed microscopically and
morphometrically in a single- or double-blinded way. To
analyze semiquantitatively for glomerular matrix accu-
mulation, 20 glomeruli from each animal were selected
randomly, and scoring of relative area of mesangial ma-
trix was as follows: 0, little or no detectable mesangial
matrix; 1+, detectable mesangial matrix of about one
fourth of glomerular area; 2+, detectable mesangial ma-
trix of one fourth to one half of glomerular area; 3+, de-
tectable mesangial matrix of one half to three fourths of
glomerular area; and 4+, detectable mesangial matrix of
three fourths to total of glomerular area. The number of
glomeruli showing a lesion of 0, 1+, 2+, 3+, or 4+ was set
as n0, n1, n2, n3, or n4, respectively, and correspondingly.
Twenty glomeruli were examined independently and then
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fibrosis score was obtained by the following formula:
[(0 × n0 + 1 × n1 + 2 × n2 + 3 × n3 +4 × n4)/20] ×
100. Tubulointerstitial fibrosis was scored semiquantita-
tively using a previously published method [36]. Cortical
tubulointerstitial fields were examined under 40× objec-
tive with a 2.5 × 2.5 mm2 ocular grid. A minimum of 10
fields was assessed in each section. The following semi-
quantitative score was used: 0, normal insterstitium and
tubules; 1+, less than 10% of fibrosis with minimal in-
terstitial thickening between tubules; 2+, 10% to 25% fi-
brosis with moderate interstitial thickening between the
tubules; and 3+, 26% to 50% fibrosis with severe intersti-
tial thickening between the tubules. Final tubular fibrosis
score in each individual was averaged from 10 different
fields.
To assess renal cell proliferation, kidney sections were
stained for proliferating cell nuclear antigen (PCNA)
(1:3000 dilution) (Sigma Chemical Co.) using Vectas-
tain ABC kit (Vector laboratories, Inc., Burlingame, CA,
USA). Renal tubular cells and interstitial cells with dis-
tinct and intense staining were counted and mean number
of proliferating cells was determined by counting PCNA-
positive cells in 10 fields per tissue section at a magnifica-
tion of 200× with a 0.5 × 0.5 mm2 ocular grid.
To assess TGF-b1 and collagen I immunostaining, the
kidney sections were stained with rabbit polyclonal anti-
TGF-b1 (1:200 dilution) (Santa Cruz Biotechnology) or
mouse monoclonal anti-collagen I (1:800 dilution) (Sigma
Chemical Co.) using Vectastain ABC kit. Collagen I den-
sity was assessed by evaluating low power (4× objective)
fields of cross-sections in Adobe PhotoShop (version 5.0)
to determine the percentage of immunohistochemical-
positive staining to total tissue area.
Statistical analysis
Statistical significance was determined by one-way
analysis of variance (ANOVA) with Fisher multiple com-
parison test. All data were expressed as mean ±SEM, and
differences were considered significant at a value of P <
0.05.
RESULTS
Expression of human tissue kallikrein in DSS
rats after kallikrein gene transfer
Following intravenous injection of adenovirus encod-
ing human tissue kallikrein gene, recombinant human
kallikrein levels in rat sera and urine were measured by an
ELISA specific for human tissue kallikrein. Immunore-
active human tissue kallikrein levels in rat serum was
1068.6 ± 93.2 ng/mL (N = 7) at day 4 and reduced to
118.7 ± 25.8 ng/mL at day 12 post-gene delivery. Human
tissue kallikrein levels were also detected in rat urine
at day 7 after gene transfer (1.6 ± 0.1 lg/100 g body
weight/day, N = 7). Recombinant human tissue kallikrein
was not detectable in the sera or urine of control DSS rats
with or without injection with control virus Ad.CMV-Luc.
Effect of kallikrein gene delivery on BUN, urinary
protein, and albumin levels in DSS rats
Figure 1A shows that BUN levels in DSS rats on high
salt diet and injected with Ad.CMV-Luc were 3.1-fold
higher than in the control group fed a normal salt diet
[1.53 ± 0.54 mg/mL (N = 6) vs. 0.49 ± 0.03 mg/mL (N = 5)
P < 0.05]. Kallikrein gene transfer significantly reduced
salt-induced BUN levels as compared to the luciferase
group at 14 days post-gene delivery [0.59 ± 0.12 mg/dL
(N = 7) vs. 1.53 ± 0.54 mg/mL (N = 6) P < 0.05]. At
7 days post-gene delivery, high salt diet increased urinary
total protein levels compared to DSS rats on a normal
salt diet [63.2 ± 6.3 mg/day/100 g body weight (N = 6) vs.
47.9 ± 3.2 mg/day/100 g body weight (N = 5) P < 0.05]
(Fig. 1B), whereas kallikrein gene transfer significantly
reduced urinary protein levels compared to the luciferase
group [43.9 ± 3.5 mg/day/100 g body weight (N = 7) vs.
63.2 ± 6.3 mg/day/100 g body weight (N = 6) P < 0.01]
(Fig. 1B). Urinary albumin levels corroborate with these
results, as a similar reduction of albumin levels were ob-
served in the kallikrein group compared to the luciferase
group [19.7 ± 1.7 mg/day/100 g body weight (N = 7) vs.
33.3 ± 4.0 mg/day/100 g body weight (N = 6) P < 0.01]
(Fig. 1C).
Effect of kallikrein gene transfer on fibrosis
scores and collagen type I immunostaining
Renal fibrosis was analyzed semiquantitatively by
staining kidney section with sirius red, which stained cy-
toplasm yellow and collagen red [35, 37]. Only a small
amount of fibrillar collagen was present in renal tubular
interstitium of control rats on a normal diet (Fig. 2A).
Six weeks of high salt intake resulted in a large area of
collagen deposition in the glomerular and interstitial ar-
eas (Fig. 2A). However, kallikrein gene transfer led to a
reduction of glomerular collagen accumulation and inter-
stitial fibrosis as compared to kidneys in rats injected with
control adenovirus (Fig. 2A). Semiquantitative analysis
of glomerular fibrosis and tubular fibrosis showed that
kallikrein gene delivery markedly reduced salt-induced
glomerular fibrosis scores [1.7 ± 0.1 (N = 7) vs. 2.5 ± 0.2
(N = 6) P < 0.01] and tubular fibrosis scores [1.6 ± 0.2
(N = 7) vs. 2.5 ± 0.3 (N = 5) P < 0.01], as compared to
the control luciferase group (Fig. 2B).
Collagen type I is the major type of interstitial collagen,
which is not present in normal glomeruli [38]. In control
kidney sections, type I collagen was localized primarily
surrounding the blood vessels with light staining around
Bowman’s capsule, identified by immunohistochemistry
(Fig. 2C). In the kidney sections from rats on a high salt
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Fig. 1. Blood urea nitrogen and urinary pro-
tein levels after kallikrein gene delivery. (A)
Blood urea nitrogen (BUN) levels. Blood
was collected at 14 days after gene transfer.
Kallikrein reduces salt-induced BUN. Values
are expressed as mean ± SEM (N = 5 to 7).
(B and C) Total urinary protein and urinary
albumin levels. Urine samples were collected
at 7 days after gene delivery. Kallikrein gene
delivery attenuated salt-induced proteinuria.
Values are expressed as mean ± SEM (N = 5
to 7).
diet and injected with the luciferase gene, extensive areas
of type I collagen were observed in the renal interstitium
(mostly around distal tubules) and periglomeruli. Occa-
sional staining was also found in sclerotic glomeruli as
well as surrounding glomeruli (Fig. 2C). In sections of
the kidney from rats injected with the kallikrein gene,
less interstitial collagen I was evident as compared to the
luciferase group (Fig. 2C). Figure 2D shows semiquan-
titative results from collagen I staining. High salt diet
markedly increased renal collagen I staining as compared
to normal control [2.8 ± 0.4% (N = 6) vs. 1.2 ± 0.1% (N =
5) P < 0.01], whereas kallikrein gene delivery significantly
reduced salt-induced collagen deposition [1.9 ± 0.1%
(N = 7) vs. 2.8 ± 0.4% (N = 6) P < 0.05].
Effect of kallikrein gene transfer
on renal cell proliferation
Renal cell proliferation was determined by PCNA im-
munohistochemistry. Figure 3 shows that, compared to
rats on a normal diet, a high salt diet significantly in-
creased renal cellular proliferation primarily in proximal
tubular cells, although some staining was also seen in in-
terstitial and glomerular cells [24 ± 3 cells/field (N = 6)
vs. 9 ± 1 cells/field (N = 5) P < 0.01]. Kallikrein gene
delivery markedly reduced renal tubular cell and intersti-
tial cell proliferation as compared to the luciferase group
[16 ± 1 cells/field (N = 7) vs. 24 ± 3 cells/field (N = 6)
P < 0.05].
Effect of kallikrein gene transfer on urinary
nitric oxide and cGMP levels
As shown in Figure 4A, high salt intake in DSS rats sig-
nificantly reduced urinary (or renal) nitrite/nitrate levels
compared to rats on a normal salt diet [1.1 ± 0.1 lmol/
day/100 g body weight (N = 6) vs. 2.5 ± 0.2 lmol/day/100 g
body weight (N = 5) P < 0.01]. Kallikrein gene transfer
significantly increased nitrite/nitrate levels as compared
to DSS rats on a high salt diet (1.6 ± 0.1 lmol/day/100 g
body weight (N = 7) vs. 1.1 ± 0.1 lmol/day/100 g body
weight (N = 6) P < 0.05). Similarly, urinary cGMP lev-
els increased significantly after kallikrein gene delivery as
compared to control rats receiving Ad.CMV-Luc [13.0 ±
0.9 nmol/day 100 g body weight (N = 7) vs. 8.0 ± 0.8 nmol/
day/100 g body weight (N = 6) P < 0.05] (Fig. 4B).
Effect of kallikrein gene delivery on NADH/NADPH
oxidase activity and superoxide generation
To determine the effect of kallikrein gene trans-
fer on salt-induced oxidative stress, we measured
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Fig. 2. Evaluation of renal fibrosis in kidney
cortex. (A) Representative histologic sections
of kidney cortex. Kidney sections were stained
with sirius red, which stained cytoplasm yel-
low and collagen red. Normal glomeruli and
tubular interstitium are shown in the control
group. Large areas of extracellular matrix ap-
peared in the glomerular mesangial area and
tubulointerstitium in the high salt Ad.CMV-
Luc group. Glomerular and tubular lesions
were obviously attenuated in the Ad.CMV-
cHK group. (B) Degree of glomerular and
tubular fibrosis. Values are presented as mean
± SEM (N = 5 to 7). Glomerular fibrosis and
tubular fibrosis were scored as described in the
Methods section. (C) Immunohistochemical
staining for type I collagen in renal sections.
Very light collagen I staining was observed in
control group. Large areas of collagen I stain-
ing appeared in the interstitium of Ad.CMV-
Luc. Some glomeruli also stained positively.
Less collagen I positive areas were seen in the
Ad.CMV-cHK. (D) Collagen I density. Values
are expressed as mean ± SEM (N = 5 to 7).
NADH/NADPH oxidase activities in renal extracts us-
ing luminescence assay. High salt diet in DSS rats caused
marked increases in NADH and NADPH oxidase activi-
ties [NADH 1.2 ± 0.3 relative light units/mg protein/min
(N = 6) vs. 0.17 ± 0.04 relative light units/mg protein/min
(N = 5) P < 0.01; NADPH 2.6 ± 0.5 relative light units/mg
protein/min (N = 6) vs. 0.7 ± 0.1 relative light units/mg
protein/min (N = 5) P < 0.01] (Fig. 5A and B), whereas
kallikrein gene significantly reduced salt-induced NADH
and NADPH oxidase activities [NADH 0.3 ± 0.04 rela-
tive light units/mg protein/min (N = 7) vs.1.2 ± 0.3 rela-
tive light units/mg protein/min (N = 6) P < 0.01; NADPH
1.1 ± 0.2 relative light units/mg protein/min (N = 7) vs.
2.6 ± 0.5 relative light units/mg protein/min (N = 6) P <
0.01] (Fig. 5A and B). NADH/NADPH oxidase is the
primary source of superoxide in the kidney [39]. Consis-
tent with these results, high salt intake significantly in-
duced renal superoxide formation compared to control
rats on normal salt diet [6.3 ± 1.5 nmol/mg protein/min
(N = 6) vs. 2.3 ± 0.9 nmol/mg protein/min (N = 5) P <
0.05] (Fig. 5C). Kallikrein gene transfer markedly re-
duced salt-induced superoxide formation as compared
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Fig. 4. Urinary nitrite/nitrate (NOx) levels (A) and urinary cyclic
guanosine monophosphate (cGMP) (B) levels. Urine samples were col-
lected at 7 days after gene delivery. Values are expressed as mean ±SEM
(N = 5 to 7).
to the luciferase group [2.6 ± 0.6 nmol/mg protein/min
(N = 7) vs. 6.3 ± 1.5 nmol/mg protein/min (N = 6) P <
0.05] (Fig. 5C).
Effect of kallikrein gene transfer on TGF-b1
expression and localization
TGF-b1 mRNA levels in the kidney were analyzed by
Northern blot analysis using GAPDH mRNA as load-
ing control (Fig. 6A). Densitometric analysis indicated
that kallikrein gene delivery significantly reduced salt-
induced ratio of TGF-b1/GAPDH mRNA as compared
to the control luciferase group. Figure 6B shows Western
blot analysis for TGF-b1 protein using b-actin protein
as loading control. Densitometric analysis showed that
high salt diet increased TGF-b1/b-actin protein about
15-fold, whereas kallikrein gene transfer significantly re-
duced TGF-b1/b-actin protein to only 8.2-fold compared
to the rats on a normal salt diet.
TGF-b1 immunohistochemistry showed that TGF-b1
protein was primarily localized in the proximal tubules
and present in the protein casts as well as in glomerular
compartments. Immunohistochemical staining of TGF-
b1 protein in the kidney showed that very few positively
stained proximal tubules were observed in the control
group (Fig. 6C). Large areas of intense staining were
present in swollen proximal tubules found in the lu-
ciferase group. TGF-b1 immunoreactivity was found in
podocytes and mesangial cells of damaged glomeruli in
the luciferase group (Fig. 6C). However, fewer TGF-b1–
positive proximal tubules and glomeruli were found in
the rats receiving the kallikrein gene (Fig. 6C).
DISCUSSION
This is the first study to demonstrate that tissue
kallikrein protects against salt-induced renal function im-
pairment and renal fibrosis. High salt diet in DSS rats
causes renal dysfunction and renal injury as evidenced
by elevation in BUN and proteinuria levels, which are
indicators of renal dysfunction. Kallikrein gene transfer
significantly reduced salt-induced renal cell proliferation,
ECM protein and collagen deposition in glomeruli and
tubular interstitium, resulting in attenuation of glomeru-
lar and tubular interstitial fibrosis. Salt loading in DSS rats
markedly reduced nitric oxide levels compared to rats on
normal diet, whereas kallikrein gene transfer significantly
increased nitric oxide levels. It has been well documented
that nitric oxide production is impaired in DSS rats fed a
high salt diet [40, 41], implying that nitric oxide bioavail-
ability plays an important role in the risk for cardiovascu-
lar and renal complications. Thus, the ability of kallikrein
gene transfer to up-regulate nitric oxide formation is sig-
nificant. Our results showed that DSS rats on high salt in-
take do not have a significant reduction in urinary cGMP
levels compared to DSS rats receiving a low salt diet.
Most likely, this is due to other factors that may contribute
to cGMP production besides nitric oxide, such as atrial
natriuretic peptide. Increased nitric oxide levels were in
conjunction with reduced NADH/NADPH oxidase and
superoxide anion formation. Oxidative stress may under-
lie the pathogenesis resulting in acute and chronic renal
diseases, as characterized by decreased renal function and
induced proliferation of renal cells [11, 12, 39]. Our re-
sults indicate that reduced nitric oxide bioavailability and
increased oxidative stress may be a contributing factor in
salt-induced renal injury and fibrosis in DSS rats.
Oxidative stress has been shown to contribute to salt-
sensitive hypertension in DSS rats and the accompany-
ing renal damage [15]. We showed that kallikrein gene
transfer significantly restored nitric oxide levels, which
was accompanied by reduced oxidative stress and renal
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Fig. 5. Determination of oxidative stress in renal extracts. (A) NADH and (B) NADPH oxidase activity in renal extracts. Kallikrein gene delivery
decreased salt-induced NADH/NADPH oxidase activities in the renal cortex collected two weeks after gene delivery. Values are expressed as mean
± SEM (N = 5 to 7). (C) Superoxide generation in the renal tissue extracts. Renal cortex was collected two weeks after kallikrein gene transfer.
Kallikrein reduced salt-induced superoxide formation. Values are expressed as mean ± SEM (N = 5 to 7). rlu, relative light unit.
injury in hypertensive DSS rats after salt loading. Nitric
oxide induces oxidation of sulfhydryl groups in the cys-
teine residue of membrane and cytosolic components of
NADH/NADPH oxidase and inhibits the assembly pro-
cess of NADH/NADPH oxidase [21]. Therefore, inhibi-
tion of NADH/NADPH oxidase activities by nitric oxide
leads to reduced ROS formation. In addition, nitric oxide
can scavenge superoxide anions and thus reduce oxida-
tive stress [42].
Stimulated ROS initiate a number of signaling cascades
leading to renal cell proliferation and progressive accu-
mulation of ECM protein via activation of transcription
and production of TGF-b1 [13, 43, 44]. TGF-b plays a
key role in matrix synthesis and degradation in several
renal diseases [45, 46]. In agreement with a previous re-
port that TGF-b1 expression is induced in kidney of DSS
rats on a high salt diet [17], we demonstrated that high
salt intake led to increases in renal TGF-b1 mRNA and
protein levels. Immunohistochemical staining revealed
that TGF-b1 protein was predominately localized in the
damaged renal proximal tubules and glomeruli. This local
generation of TGF-b1 could directly stimulate fibroblast
proliferation and ECM protein accumulation resulting
in both interstitial and glomerular fibrosis. This assump-
tion is supported by a previous study showing stimulation
of cortical fibroblast proliferation and collagen synthe-
sis in vitro after addition of conditioned media isolated
from cultured proximal tubule cells, which was blocked
by TGF-b neutralizing antibody [47]. Kallikrein gene
delivery inhibited salt-induced TGF-b1 expression and
immunoreactive TGF-b levels as well as collagen ac-
cumulation in the kidney. In mesangial cells cocultured
with glomerular endothelial cells, nitric oxide has been
shown to reduce TGF-b1 mRNA as well as TGF-b1
and collagen synthesis, partially by inhibiting protein ki-
nase C activity [48]. Therefore, the beneficial effect of
kallikrein on salt-induced renal fibrosis may be attributed
to increased nitric oxide bioavailability. However, even
though nitric oxide and TGF-b1 levels were significantly
reversed after kallikrein gene delivery, they were not nor-
malized to control levels. This may indicate that addi-
tional mechanisms are involved in kallikrein’s protective
effect against salt-induced renal fibrosis. Furthermore,
since NADH/NADPH oxidase activity and superoxide
levels were completely abolished by kallikrein gene de-
livery, this would suggest that ROS may play a role in
regulating nitric oxide and TGF-b1 levels as well as other
factors that contribute to renal fibrosis.
Exposure of kidney to high pressure leads to secretion
of vasoactive substances, cytokines, and growth factors
such as platelet-derived growth factor, basic fibroblast
growth factor, and TGF-b [49]. TGF-b and/or other cy-
tokines are able to directly or indirectly stimulate the pro-
liferation of tubular and interstitial cells and contribute
to the production of ECM proteins [49–52]. Using im-
munohistochemical staining for PCNA, a marker of cell
proliferation [53], we observed that diffuse renal tubular
and interstitial positive cells were associated with renal
fibrosis in response to salt loading, whereas proliferat-
ing cells were significantly reduced in the rats injected
with the kallikrein gene. Suppression of proliferating re-
nal cells may account for reduction of collagen deposition
in the kidneys. The inhibitory effect of kallikrein on renal
cell proliferation may be, in part, due to suppression of a
TGF-b–mediated signaling event.
In the present study, we showed that kallikrein gene
delivery reduced BUN, proteinuria, NADH/NADPH
oxidase activity, and superoxide formation to levels sim-
ilar to DSS rats on a normal salt diet. These results
suggest that kallikrein is capable of protection against
salt-induced renal damage by suppression of oxidative
stress. However, since salt-induced renal fibrosis causes
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Fig. 6. Effect of kallikrein gene delivery on TGF-b expression. (A) Representative Northern blot analysis shows renal mRNAs for transforming
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structural changes in the kidney, the reduction of oxida-
tive stress measured at 2 weeks after gene delivery may
reflect the time point at which the biochemical signaling is
altered while the kidney is still undergoing morphologic
and functional changes. This would imply that the reduc-
tion of oxidative stress we observed occurred before the
changes in kidney morphology and function were com-
plete.
Our previous study showed that after more than
5 weeks of high salt loading (or 11 days after virus in-
jection), DSS rats injected with control virus had a sys-
tolic blood pressure value of 240 mm Hg, which was
slightly reduced by 20 mm Hg in the DSS rats receiv-
ing the kallikrein gene [28]. It is likely that this decrease
in blood pressure by kallikrein gene transfer may poten-
tially contribute to the renal protective effects observed
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in the current study. However, the blood pressure of rats
receiving the kallikrein gene was still 50 to 60 mm Hg
higher than DSS rats on low salt [28]. Based on this data,
renal protection mediated by kallikrein gene transfer ap-
pears to be only partially dependent on blood pressure
change. In support of this notion, it has been shown that a
long-term infusion of rat urinary kallikrein in DSS rats on
high salt intake was able to attenuate renal injury with-
out affecting systolic blood pressure [54]. Furthermore,
infusion of the B2 receptor antagonist HOE140 in salt-
loaded DSS rats abolished kallikrein’s protective effect
in the kidney, but had no effect on the time-dependent
rise in blood pressure [55]. Taken together, these re-
sults suggest that kallikrein/kinin attenuates salt-induced
kidney damage through mechanisms independent of
blood pressure reduction.
Our previous studies indicate that there are no signif-
icant differences between the results from rats treated
with the same experimental procedure with or without
injection of adenovirus containing a reporter gene. For in-
stance, Agata et al [56] demonstrated no significant differ-
ences of neointima formation in rat artery after balloon
angioplasty with or without Ad.CMV-Luc gene transfer.
In addition, Wolf et al [57] showed that in rats subjected
to 5/6 renal mass reduction with or without receiving
Ad.CMV-Luc gene transfer, no significant differences
were observed in blood pressure, BUN, indices of re-
nal and cardiac injury, or urinary kinin, nitric oxide, and
cGMP levels. Furthermore, our previous study showed
that the blood pressure did not differ between DSS rats
fed 4% NaCl injected with or without control virus [58].
Overall, these findings provide evidences that the injec-
tion of control virus alone does not contribute to any ad-
ditional effects in our animal models as compared to rats
without injection. In addition, overexpression of human
tissue kallikrein in transgenic mice may result in inflam-
matory response, as we observed changes in the cytoar-
chitecture of several lymphatic organs [59]. However, we
have shown that kallikrein gene transfer into genetically
hypertensive rats does not cause an immune response, as
determined by the absence of antibodies against human
tissue kallikrein or its DNA in the sera after gene trans-
fer [60, 61]. These results indicate that somatic delivery of
the kallikrein gene does not elicit an immune response. It
should also be noted that endogenous kallikrein is primar-
ily located in the distal nephron of the kidney, whereas
exogenous kallikrein after systemic gene transfer can be
expressed at various sites of the kidney; secreted into
the circulation; and excreted in the urine [25, 28]. There-
fore, kinins released by exogenous kallikrein activity may
act on regions of the kidney that are not restricted to
the location of endogenous kallikrein. In this regard, it
is possible that human tissue kallikrein transfer may af-
fect areas that are not directly regulated by endogenous
kallikrein.
CONCLUSON
The current study demonstrated that kallikrein gene
delivery offers protection against salt-induced renal cell
proliferation and fibrosis, due most likely to reduced
oxidative stress and TGF-b1 expression. The beneficial
effects of kallikrein on renal fibrosis may be mainly medi-
ated via activation of nitric oxide/cGMP signaling path-
ways. The finding that kallikrein/kinin attenuates renal
fibrosis provides significant insight into future therapeu-
tic applications in treating salt-induced end-stage renal
diseases.
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